利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.033 秒)

    Methods of screening for pharmacologically active compounds for the treatment of tumour diseases
    5.
    发明授权
    Methods of screening for pharmacologically active compounds for the treatment of tumour diseases 失效
    筛选用于治疗肿瘤疾病的药理活性化合物的方法

    公开(公告)号：US06383733B1

    公开(公告)日：2002-05-07

    申请号：US09155716

    申请日：1999-02-16

    申请人： Hartmut Beug ,  Martin Oft ,  Ernst Reichmann ,  Karl-Heinz Heider

    发明人： Hartmut Beug ,  Martin Oft ,  Ernst Reichmann ,  Karl-Heinz Heider

    IPC分类号： C12Q100

    CPC分类号： A61K39/3955 ,  A61K38/179

    摘要： Pharmaceutical compositions containing as active compound a substance which inhibits the activity of TGF&bgr; on tumour cells of epithelial origin, for the treatment of epithelial, invasive tumour diseases which are characterized by a reversible transition of the cells from an epithelial, non-invasive state into a fibroblastoid, invasive state. The pharmaceutical composition contains a TGF&bgr; inhibitor, preferably combined with an Ras inhibitor. Process for screening substances for the treatment of epithelial, invasive tumour diseases.

    摘要翻译： 含有作为活性化合物的药物组合物，其抑制TGFbeta在上皮起源的肿瘤细胞上的活性，用于治疗上皮，浸润性肿瘤疾病，其特征在于细胞从上皮，非侵入状态向 成纤维细胞，侵袭状态。 药物组合物含有TGFbeta抑制剂，优选与Ras抑制剂组合。 筛选用于治疗上皮，侵袭性肿瘤疾病的物质的方法。

    SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES
    9.
    发明申请
    SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES 审中-公开
    CD37抗体在CLL血液样品中的超高效

    公开(公告)号：US20120189618A1

    公开(公告)日：2012-07-26

    申请号：US13182471

    申请日：2011-07-14

    申请人： Stephan Stilgenbauer ,  Thorsten Zenz ,  Karl-Heinz Heider

    发明人： Stephan Stilgenbauer ,  Thorsten Zenz ,  Karl-Heinz Heider

    IPC分类号： A61K39/395 ,  A61P35/02 ,  C12N5/071 ,  A61P35/00

    CPC分类号： C07K16/2896 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention describes CD37 antibodies, especially A2 and B2, for the treatment of patients with CLL, especially of patients belonging to a “high risk” or “ultra-high risk” group of patients. Those patients are either patients who are refractory to fludarabine treatment or patients who carry a genetic marker which is indicative for poor prognosis or increased risk of treatment failure, e.g. patients with TP53 dysfunction or deletion of chromosome 17p13, or patients after failure to previous anti-CD20 treatment. The ability of A2 and B2 to deplete CLL cells is high both in patient samples derived from patients with normal risk and with increased risk (“high risk” patients) and clearly superior to that of rituximab and alemtuzumab.

    摘要翻译： 本发明描述了用于治疗CLL患者，特别是属于“高风险”或“超高危”患者的患者的CD37抗体，特别是A2和B2。 那些患者是氟达拉滨治疗难治的患者或携带遗传标记的患者，其指示预后不良或治疗失败风险增加，例如， 患有TP53功能障碍或缺失染色体17p13的患者，或患者在以前的抗CD20治疗失败后。 来自患有正常风险和风险增加（“高风险”）患者的患者样本中A2和B2消耗CLL细胞的能力高，明显优于利妥昔单抗和阿仑单抗。